Expanded Access to Investigational Drugs

Early Patient Access to Takeda Oncology Investigational Medicines

Consistent with Takeda’s philosophy of Takeda-ism and Values, Takeda is committed to providing safe, fair and sustainable patient access to its products at different stages of lifecycle development.

In some cases, Takeda may be able to provide patients access to its investigational drugs outside of a clinical trial if certain conditions are met and if permitted by local law and regulation. The use of investigational drugs outside of a clinical trial is known as Expanded Access. Expanded Access may not always be available and requires the individual patient meet certain eligibility conditions:

  • Has a diagnosis of a serious, life-threatening or severely debilitating disease
  • Has no alternative treatment options available
  • Is unable to participate in a clinical trial

In addition, Takeda will consider providing Expanded Access only if the risk/benefit profile of the investigational drug is favorable in light of the available safety and efficacy information and the treating physician’s assessment of the patient’s medical condition.

For additional information about Takeda’s Expanded Access approach, please click here.

Requesting Access to Takeda Investigational Drugs

Licensed healthcare professionals in areas outside of the United States who are interested in the following Takeda investigational products may request further information using the below contact details.

Brigatinib (ALUNBRIG®)

Clinigen Group plc

Online Request: https://cliniport.co.uk/
Email: {MAIL}

Country Telephone Number Fax Number
UK +44 1283 494 340 +44 1283 494 341
Belgium 065 250 307 +44 1283 494 341
France 0800 903 406 0805 109 994
Germany 069 2222 3413 0800 589 2457
Italy 800 977 669 800 977 686
Spain 800 600 217 800 600 218
All other countries +44 1283 494 340 +44 1283 494 341

Mifamurtide (MEPACT®)

Clinigen Group plc

Tel: +44 1932 824 123
Fax: +44 1932 824 323
Email: row@clinigengroup.com

Brentuximab vedotin (ADCETRIS®)

Clinigen Group plc

Tel: +44 1932 824 123
Fax: +44 1932 824 323
Email: row@clinigengroup.com

Ixazomib (NINLARO®)

Clinigen Group plc

Online Request: https://cliniport.co.uk/
Tel: +44 1283 494 340
Fax: +44 1283 494 341
Email: {MAIL}

For requests to other Takeda investigational drugs, please email expandedaccess@takeda.com